Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study

NCT07482670 | Not Yet Recruiting DMC

• 1 other identifier: 202602023
• Study Type: observational
• Target: 32
• Locations: 0 countries
• Sites: N/A

Brief Summary

1.1. Main Objectives The objective response rate (ORR) determined by the researchers based on RECIST v1.1 was used to evaluate the efficacy of systemic therapy (carrycept combined with apatinib) in combination with or without local treatment (surgery, radiotherapy, or ablation therapy) for patients with advanced hepatocellular carcinoma with pulmonary metastases. 1.2. Secondary objectives Through efficacy indicators such as progression-free survival (PFS) and objective response rate (ORR) determined by researchers based on RECIST v1.1 and mRECIST, evaluate the efficacy of systemic therapy (carrietumab combined with apatinib) combined or not with local treatment (surgery, radiotherapy, or ablation therapy) for patients with advanced hepatocellular carcinoma with pulmonary metastases. Evaluate the safety of combining systemic therapy (caretuximab-rbsm in combination with apatinib) with or without local treatment (surgery, radiotherapy, or ablation therapy) for patients with advanced hepatocellular carcinoma with pulmonary metastases. 1.3. Exploratory Purpose Evaluate the cumulative duration (the sum of the time spent in a NED state) and the safety of local treatments for patients who have undergone comprehensive treatment and have no detectable active lesions on imaging studies (NED). Explore the correlation between biomarkers and the efficacy of combined treatment regimens. Explore the relationship between the number, diameter, and treatment outcomes of pulmonary metastases in hepatocellular carcinoma.

Conditions

Hepatecellular Carcinoma

Outcome Measures

Primary Outcomes (1)

• Objective response rate

  From enrollment to the end of treatment at Week 12

Study Arms (1)

Camrelizumab plus Rivoceranib and Local Therapy

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Pulmonary metastases are the most common type of extrahepatic metastasis in liver cancer, accounting for approximately 40%. Patients with this condition have poor prognoses, with a total survival period of only 6 to 10 months. The overall survival rate at one year and the cancer-specific survival rate are only 12.8% and 15.3%, respectively. Therefore, improving the treatment outcomes for patients with pulmonary metastases from liver cancer has become a research focus and challenge. This study prospectively collected data on the efficacy and safety of systemic treatment (carryliqumab combined with apatinib) and/or local treatments (surgery, radiotherapy, or ablation therapy) for patients with locally advanced or metastatic hepatocellular carcinoma that has not been treated systemically.

You may qualify if:

• The patient voluntarily participates in this study and signs an informed consent form.
• Age: 18 to 85 years old, both male and female are eligible.
• Patients with hepatocellular carcinoma (HCC) confirmed through histopathological examination of tumor tissue or imaging assessments \[refer to the Guidelines for the Diagnosis and Treatment of Primary Hepatocellular Carcinoma (2024 Edition)\].
• There are extrahepatic pulmonary metastases that have not been treated locally, and the number of these metastases is ≤5.
• Has not received any form of systematic treatment for HCC.
• There must be at least one measurable lesion (according to the RECIST v1.1 criteria, this measurable lesion must have a longitudinal diameter ≥ 10 mm on spiral CT scans or a short diameter ≥ 15 mm for enlarged lymph nodes; lesions that have previously received local treatment and have clearly progressed according to the RECIST v1.1 standards can be considered target lesions).
• Neutrophil-to-lymphocyte ratio (NLR) of less than or equal to 3.
• The Child Pugh liver function classification is Grade A or B (≤7).
• The Eastern Cooperative Oncology Group (ECOG) behavioral status is 0 or 1 for patients in the eastern United States.
• Good lung function, expected to be able to tolerate surgery or localized treatment.
• Other major organ functions are generally normal (the blood system, kidneys, etc., function well).
• Muscular marrow function is adequate: white blood cell count ≥ 4.0 × 10\^9/L, absolute neutrophil count (ANC) ≥ 2.0 × 10\^9 / L, platelet count ≥ 100 × 10 \^ 9 / L, hemoglobin concentration ≥ 90 g/L (no blood transfusions, no use of hematopoietic factors, and no medication correction within 2 weeks prior to the first administration).
• For patients not receiving anticoagulant therapy, the INR (International Normalized Ratio) and APTI (Activated Partial Thromboplastin Time) values are ≤ 1.5 times the upper limit of normal.
• Sufficient renal function: creatinine clearance ≥ 60 mL/min.
• Patients with active hepatitis B virus (HBV) infection must receive anti-HBV treatment prior to the initiation of the study treatment and must be willing to undergo antiviral therapy throughout the study period. Patients with hepatitis C virus (HCV) RNA-positive status must receive antiviral treatment according to local standard treatment guidelines and have liver function levels within the range of CTCAE Grade 1 elevation.

You may not qualify if:

• Patients who meet any of the following criteria will not be eligible to participate in this study:
• Known cases of cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma, and fibrolamellar cell carcinoma; having had an active malignant tumor other than HCC within 5 years or concurrently. Limited-stage tumors that have been cured, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial carcinoma, cervical intraepithelial carcinoma, and breast intraepithelial carcinoma, can be included.
• Has previously received anti-cancer treatments targeting metastatic lesions.
• The site of extrahepatic metastasis is not the lungs, or there are more than 2 distant metastasized organs (including 2).
• Suffering from any severe infection, serious mental or physical illness, or laboratory test abnormalities that are uncontrollable, which may pose an unacceptable risk, negatively impact trial compliance, or affect the administration, distribution, metabolism, and excretion of the investigational drug. Examples include unstable heart disease, chronic kidney disease, poorly controlled diabetes, mood disorders, mental disorders, central nervous system abnormalities, chronic diarrhea, ascites, and pleural effusions requiring treatment.
• Suffers from hypertension and cannot achieve adequate control with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg). It is permissible to use antihypertensive treatment to achieve these parameters. Has previously experienced a hypertensive crisis or hypertensive encephalopathy.
• Infection with human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) (or active viral hepatitis).
• Received experimental treatments from other clinical studies concurrently during the course of this trial.
• Long-term use of immunosuppressive agents following organ transplantation.
• According to the researchers' assessment, the subject may have other factors that could lead to the forced discontinuation of this study. These include non-compliance with the protocol, the presence of other serious conditions (including mental illnesses) requiring concurrent treatment, significant laboratory abnormalities, a history of substance abuse or drug use, combined with psychological, social, familial, or geographic factors, which could impact the subject's safety or the collection of data and samples.

Sponsors & Collaborators

• Xiangya Hospital of Central South University: lead

Related Publications (21)

• Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: a population-based study. Cancer Manag Res. 2019 Apr 8;11:2759-2768. doi: 10.2147/CMAR.S192896. eCollection 2019.

  PMID: 31040715 BACKGROUND

• Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, Diaz A, Llarch N, Iserte G, Molla M, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Yanagihara TK, Ayuso C, Torres F, Bruix J. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. J Hepatol. 2026 Mar;84(3):631-654. doi: 10.1016/j.jhep.2025.10.020. Epub 2025 Oct 27.

  PMID: 41151697 BACKGROUND

• Vogel A, Chan SL, Dawson LA, Kelley RK, Llovet JM, Meyer T, Ricke J, Rimassa L, Sapisochin G, Vilgrain V, Zucman-Rossi J, Ducreux M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 May;36(5):491-506. doi: 10.1016/j.annonc.2025.02.006. Epub 2025 Feb 20. No abstract available.

  PMID: 39986353 BACKGROUND

• Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, Liu J, Ren Z, Xiong J, Mao X, Zhang L, Yang J, Li L, Chen X, Wang Z, Gu K, Chen X, Pan Z, Ma K, Zhou X, Yu Z, Li E, Yin G, Zhang X, Wang S, Wang Q. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res. 2021 Feb 15;27(4):1003-1011. doi: 10.1158/1078-0432.CCR-20-2571. Epub 2020 Oct 21.

  PMID: 33087333 BACKGROUND

• Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, Jia Y, Shi J, Zhang L, Liu X, Qiao M, Chen X, Su C, Yu H, Zhou C, Zhang J, Camidge DR, Hirsch FR. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Cancer Immunol Res. 2019 Apr;7(4):630-643. doi: 10.1158/2326-6066.CIR-17-0640. Epub 2019 Feb 12.

  PMID: 30755403 BACKGROUND

• Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2.

  PMID: 38039993 BACKGROUND

• Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24.

  PMID: 37499670 BACKGROUND

• Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.

  PMID: 35798016 BACKGROUND

• Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.

  PMID: 34143971 BACKGROUND

• Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.

  PMID: 32402160 BACKGROUND

• Sakamoto Y, Kubota K, Mori M, Inoue K, Abe H, Harihara Y, Bandai Y, Makuuchi M. Surgical management for adrenal gland metastasis of hepatocellular carcinoma. Hepatogastroenterology. 1999 Mar-Apr;46(26):1036-41.

  PMID: 10370663 BACKGROUND

• Hu Z, Li W, Huang P, Zhou Z, Xu J, Xu K, Wang J, Zhang H. Therapeutic significance and indications of pulmonary metastasectomy for hepatocellular carcinoma following liver resection. Int J Surg. 2017 Dec;48:23-31. doi: 10.1016/j.ijsu.2017.09.075. Epub 2017 Oct 5.

  PMID: 28987561 BACKGROUND

• Ikegami T, Yoshizumi T, Kawasaki J, Nagatsu A, Uchiyama H, Harada N, Harimoto N, Itoh S, Motomura T, Soejima Y, Maehara Y. Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma. Anticancer Res. 2017 Feb;37(2):891-895. doi: 10.21873/anticanres.11395.

  PMID: 28179348 BACKGROUND

• Soliman H, Ringash J, Jiang H, Singh K, Kim J, Dinniwell R, Brade A, Wong R, Brierley J, Cummings B, Zimmermann C, Dawson LA. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol. 2013 Nov 1;31(31):3980-6. doi: 10.1200/JCO.2013.49.9202. Epub 2013 Sep 23.

  PMID: 24062394 BACKGROUND

• Kashima M, Yamakado K, Takaki H, Kaminou T, Tanigawa N, Nakatsuka A, Takeda K. Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. AJR Am J Roentgenol. 2010 Feb;194(2):536-41. doi: 10.2214/AJR.09.2975.

  PMID: 20093621 BACKGROUND

• Lee BM, Choi JY, Seong J. Efficacy of Local Treatment in Lymph Node Metastasis from Hepatocellular Carcinoma. Liver Cancer. 2023 Jan 18;12(3):218-228. doi: 10.1159/000529201. eCollection 2023 Aug.

  PMID: 37767066 BACKGROUND

• Long HY, Huang TY, Xie XY, Long JT, Liu BX. Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World J Clin Cases. 2021 Jul 26;9(21):5754-5768. doi: 10.12998/wjcc.v9.i21.5754.

  PMID: 34368295 BACKGROUND

• Wu W, He X, Andayani D, Yang L, Ye J, Li Y, Chen Y, Li L. Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study. J Cancer. 2017 Jul 21;8(12):2312-2318. doi: 10.7150/jca.19056. eCollection 2017.

  PMID: 28819435 BACKGROUND

• Iijima H, Kudo M, Kubo S, Kurosaki M, Sakamoto M, Shiina S, Tateishi R, Osamu N, Fukumoto T, Matsuyama Y, Murakami T, Takahashi A, Miyata H, Kokudo N. Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014-2015). Hepatol Res. 2023 Oct;53(10):895-959. doi: 10.1111/hepr.13953. Epub 2023 Sep 5.

  PMID: 37574758 BACKGROUND

• Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015 Sep;35(9):2155-66. doi: 10.1111/liv.12818. Epub 2015 Mar 25.

  PMID: 25752327 BACKGROUND

• Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. doi: 10.1016/j.jncc.2024.01.006. eCollection 2024 Mar.

  PMID: 39036382 BACKGROUND

Central Study Contacts

xin zhang

CONTACT

+86 731 8432 7919; xyyyllwyh@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 15, 2026
• First Posted: March 19, 2026
• Study Start: March 2, 2026
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: March 19, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
• Time Frame: IPD will be made available beginning 6 months after publication of the primary study results, and will be accessible for a period of 5 years thereafter.
• Access Criteria: De-identified IPD and supporting documents will be accessible to qualified researchers upon reasonable request, following review and approval of a formal research proposal. Access will be provided in compliance with ethical approval, informed consent, and applicable laws and regulations. Data will be shared via a secure, password-protected data repository.